Nanobiotix Management

Management criteria checks 2/4

Nanobiotix's El consejero delegado es Laurent Levy , nombrado en Mar 2003, tiene un mandato de 21.08 años. la remuneración anual total es €1.39M , compuesta por 27.3% salario y 72.7% primas, incluidas acciones y opciones de la empresa. posee directamente 2.42% de las acciones de la empresa, por valor de €6.49M . La antigüedad media del equipo directivo y del consejo de administración es de 4.8 años y 1.4 años respectivamente.

Key information

Laurent Levy

Chief executive officer

€1.4m

Total compensation

CEO salary percentage	27.3%
CEO tenure	21.1yrs
CEO ownership	2.4%
Management average tenure	4.8yrs
Board average tenure	1.4yrs

Recent management updates

How Should Investors React To Nanobiotix's (EPA:NANO) CEO Pay?

Dec 22

Recent updates

CEO Compensation Analysis

How has Laurent Levy's remuneration changed compared to Nanobiotix's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2023	n/a	n/a	-€59m
Mar 31 2023	n/a	n/a	-€58m
Dec 31 2022	€1m	€380k	-€57m
Sep 30 2022	n/a	n/a	-€50m
Jun 30 2022	n/a	n/a	-€43m
Mar 31 2022	n/a	n/a	-€45m
Dec 31 2021	€4m	€380k	-€47m
Sep 30 2021	n/a	n/a	-€45m
Jun 30 2021	n/a	n/a	-€43m
Mar 31 2021	n/a	n/a	-€39m
Dec 31 2020	€818k	€330k	-€34m
Sep 30 2020	n/a	n/a	-€41m
Jun 30 2020	n/a	n/a	-€48m
Mar 31 2020	n/a	n/a	-€49m
Dec 31 2019	€2m	€330k	-€51m
Sep 30 2019	n/a	n/a	-€46m
Jun 30 2019	n/a	n/a	-€42m
Mar 31 2019	n/a	n/a	-€36m
Dec 31 2018	€1m	€300k	-€30m
Sep 30 2018	n/a	n/a	-€28m
Jun 30 2018	n/a	n/a	-€27m
Mar 31 2018	n/a	n/a	-€26m
Dec 31 2017	€861k	€253k	-€26m

Compensación vs. Mercado: Laurent($USD1.50M) está por encima de la media de empresas de tamaño similar en el mercado French ($USD535.31K).

Compensación vs. Ingresos: La compensación de Laurent ha sido consistente con los resultados de la empresa en el último año.

CEO

Laurent Levy (50 yo)

21.1yrs

Tenure

€1,393,145

Compensation

Mr. Laurent Lévy, Ph.D. has been the President of the Executive Board at Nanobiotix S.A. since May 27, 2004 and its Chief Executive Officer since March 2003. Mr. Lévy has a thorough understanding of the te...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Laurent Levy	Co-Founder	21.1yrs	€1.39m	2.42% € 6.6m
Bart Van Rhijn	CFO & Member of Executive Board	2.8yrs	€866.64k	0% € 0
Anne-Juliette Hermant	Chief People Officer & Member of Executive Board	4.8yrs	€486.62k	0.30% € 814.8k
Earl Bergey	Co-Founder	21.3yrs	no data	no data
Alain Dostie	Chief Operating Officer	7.2yrs	no data	no data
Craig West	Senior Vice President of Investor Relations	no data	no data	no data
Brandon Owens	VP of Strategic Marketing & Corporate Communication	no data	no data	no data
Patrick Tricoli	Global Head of Business Development	4.8yrs	no data	no data
Margaret Galluzzi	VP & Global Head of Clinical Operations	5.3yrs	no data	no data
Ventzislav Vassilev	VP & Global Head of Safety Vigilance	3.9yrs	no data	no data
Leonard Farber	Chief Clinical and Medical Affairs Officer & Chairman of the Scientific Advisory Board	2.2yrs	no data	no data
Louis Kayitalire	Chief Medical Officer	less than a year	no data	no data

4.8yrs

Average Tenure

50yo

Average Age

Equipo directivo experimentado: NANOEl equipo directivo de la empresa se considera experimentado (4.4 años de antigüedad media).

Board Members

Name	Position	Tenure	Compensation	Ownership
Leonard Farber	Chief Clinical and Medical Affairs Officer & Chairman of the Scientific Advisory Board	no data	no data	no data
Enno Spillner	Independent Member of Supervisory Board	9.8yrs	€50.00k	no data
Christophe Douat	Supervisory Board Observer	6.8yrs	€35.00k	no data
Gary Phillips	Independent Chairman of Supervisory board	2.9yrs	€63.00k	no data
Silvia Formenti	Member of Scientific Advisory Board	1.4yrs	no data	no data
Alain Herrera	Independent Member of Supervisory Board	10.8yrs	€35.00k	no data
Anne-Marie Graffin	Independent Vice Chairman of the Supervisory Board	10.3yrs	€42.00k	no data
Hisham Mehanna	Member of Scientific Advisory Board	1.4yrs	no data	no data
Stephane Champiat	Member of Scientific Advisory Board	1.4yrs	no data	no data
Jean Bourhis	Member of Scientific Advisory Board	1.4yrs	no data	no data
Thierry Baere	Member of Scientific Advisory Board	1.4yrs	no data	no data
Christophe Tourneau	Member of Scientific Advisory Board	1.4yrs	no data	no data

1.4yrs

Average Tenure

57yo

Average Age

Junta con experiencia: NANOno se consideran experimentados ( 1.1 años de permanencia media), lo que sugiere un nuevo consejo.

Nanobiotix Management

Management criteria checks 2/4

Key information

Recent management updates

Nanobiotix S.A., Annual General Meeting, Jun 27, 2023

NANOBIOTIX Announces the Appointment of Global Medical Experts to Scientific Advisory Board

How Should Investors React To Nanobiotix's (EPA:NANO) CEO Pay?

Recent updates

Consensus revenue estimates fall by 24%

Nanobiotix S.A. announced that it has received $24.999999 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

Nanobiotix S.A. to Report Q3, 2023 Results on Nov 13, 2023

Nanobiotix S.A. has completed a Follow-on Equity Offering in the amount of $29.288592 million.

Nanobiotix S.A. has filed a Follow-on Equity Offering in the amount of $30 million.

Nanobiotix S.A. announced that it expects to receive $25 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

Nanobiotix S.A. Announces Updated Preliminary Results from Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis from Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023

Consensus revenue estimates increase by 26%

Nanobiotix S.A. Announces New Clinical Data from Phase 1 Study Evaluating Radiotherapy-Activated Nbtxr3 for Patients with Pancreatic Ductal Adenocarcinoma

New minor risk - Financial position

Nanobiotix S.A. to Report First Half, 2023 Results on Sep 26, 2023

New minor risk - Shareholder dilution

NANOBIOTIX Announces Expiration of HSR Waiting Period Regarding the Agreement for Worldwide Co-Development and Commercialization of Potential First-in-Class Radioenhancer NBTXR3

Nanobiotix S.A. Announces First Patient Injected in New Phase 1/2 Study Evaluating Radiotherapy-Activated NBTXR3 Plus Anti-PD-1 for Patients With Advanced Cancers

Consensus revenue estimates increase by 420%

Price target increased by 23% to €19.03

Nanobiotix S.A., Annual General Meeting, Jun 27, 2023

No longer forecast to breakeven

Price target increased by 15% to €25.17

We're Keeping An Eye On Nanobiotix's (EPA:NANO) Cash Burn Rate

NANOBIOTIX Announces First Patient Randomized in United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer

Price target decreased to €21.90

NANOBIOTIX Recommends Phase 2 Dose for NBTXR3 in Pancreatic Cancer

NANOBIOTIX Updates Data from its Phase 1 Immunotherapy Study, Study 1100

NANOBIOTIX Announces the Appointment of Global Medical Experts to Scientific Advisory Board

Forecast to breakeven in 2024

NANOBIOTIX Establishes Recommends Dose for Planned Registrational Study Evaluating NBTXR3 Plus Anti-PD-1 for Patients With Metastatic Head and Neck Cancer Resistant to Prior Immunotherapy

Nanobiotix S.A. and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck Cancer

NANOBIOTIX Announces the Reporting of New Data at the 2022 Annual Meeting of the American Society for Clinical Oncology

Nanobiotix S.A. Announces the Reporting of New Data At the 2022 Annual Meeting of the American Society for Clinical Oncology

Nanobiotix S.A. to Report First Half, 2022 Results on Sep 28, 2022

Is Nanobiotix (EPA:NANO) Weighed On By Its Debt Load?

Price target decreased to €22.90

Nanobiotix S.A. Announces New Data from an Open-Label Preclinical Study Evaluating the Combination of First-in-Class Radioenhancer, NBTXR3, with the Triple Blockade of PD-1, LAG-3, and TIGIT

Price target decreased to €23.18

Full year 2021 earnings: EPS and revenues miss analyst expectations

Nanobiotix Announces Publication of New Clinical Case Study Highlighting First Patient Experience of NBTXR3 Treatment for Pancreatic Cancer

Price target increased to €29.67

Nanobiotix S.A. Announces Publication of New Preclinical Immunotherapy Data Showcasing the Combination Potential of NBTXR3 With anti-PD-1 and anti-CTLA-4

Nanobiotix S.A. Announces First Patient Enrolled in NANORAY-312 Global Phase III Registrational Study of NBTXR3 in Head and Neck Cancer

Nanobiotix (EPA:NANO) Has Debt But No Earnings; Should You Worry?

Nanobiotix S.A. Announces Red Journal Publication of Preclinical Data Showing Radioenhancer NBTXR3 May 'Reprogram' the Tumor Microenvironment to Overcome Anti-PD-1 Resistance and Evoke Abscopal Effect

First half 2021 earnings released: €0.88 loss per share (vs €0.91 loss in 1H 2020)

NANOBIOTIX Announces Initiation of New Clinical Study Evaluating NBTXR3 in Lung Cancer

NANOBIOTIX Reports New Data for Potential First-in-Class Radioenhancer NBTXR3 in Combination With Anti-PD-1 Showing Local or Distant Tumor Regression in 76.9% of Evaluable Patients Regardless of Prior Anti-PD-1 Exposure

Is Nanobiotix (EPA:NANO) Using Too Much Debt?

Nanobiotix Announces Updated Results From Priority Pathways in Head and Neck Cancer and Immunotherapy for Potential First-in-class Radioenhancer NBTXR3 at 2021 Annual Meeting of the American Society for Clinical Oncology

Nanobiotix S.A. Announces New Data from its Oncology Pipeline to Be Present at the 2021 American Society of Clinical Oncology Annual Meeting

Consensus EPS estimates fall to -€1.29

Full year 2020 earnings released: €1.38 loss per share (vs €2.35 loss in FY 2019)

Full year 2020 earnings released

NANOBIOTIX and PharmaEngine, Inc. Mutually Agree to Conclude Collaboration

NANOBIOTIX Announces Positive New Preclinical Data Investigating First-In-Class Radioenhancer NBTXR3

Nanobiotix S.A. to Report Q2, 2021 Results on Sep 03, 2021

Nanobiotix Announces First Patient Injected with NBTXR3 in Esophageal Cancer

New 90-day high: €17.20

NANOBIOTIX Announces Positive First Results for Novel NBTXR3 in Rectal Cancer Study at ASCO-GI 2021

Price target raised to €25.18

How Should Investors React To Nanobiotix's (EPA:NANO) CEO Pay?

New 90-day high: €14.00

Nanobiotix S.A. has completed a Follow-on Equity Offering in the amount of $99 million.

Analysts update estimates

Nanobiotix Announces Two New Phase II Trials Evaluating NBTXR3 in Combination with Anti-PD-1 for the Treatment of Head and Neck Cancer

NANOBIOTIX Announces Positive New Pre-Clinical Data Suggesting Radioenhancer NBTXR3 Could Have A Significant Impact in Immunotherapy

Nanobiotix Announces Positive First Clinical Data Showing Conversion of Anti-PD-1 Non-Responders to Responders With Radioenhancer NBTXR3

New 90-day low: €5.72

Nanobiotix Provides Updates on Global Clinical Development Plan for First-In-Class Radioenhancer Nbtxr3 At Astro 2020

NANOBIOTIX Announces First Patient Injected with Nbtxr3 in Pancreatic Cancer and Safe to Proceed Notifications for Two Additional Trials from U.S. FDA

New 90-day low: €6.31

Analysts increase EPS estimates to -€1.76

First half earnings released

Nanobiotix S.A. has completed a Follow-on Equity Offering in the amount of €20.13 million.